The Pharmacology of Imepitoin: The First Partial Benzodiazepine Receptor Agonist Developed for the Treatment of Epilepsy

@article{Rundfeldt2013ThePO,
  title={The Pharmacology of Imepitoin: The First Partial Benzodiazepine Receptor Agonist Developed for the Treatment of Epilepsy},
  author={Chris Rundfeldt and Wolfgang L{\"o}scher},
  journal={CNS Drugs},
  year={2013},
  volume={28},
  pages={29-43}
}
Although benzodiazepines (BZDs) offer a wide spectrum of antiepileptic activity against diverse types of epileptic seizures, their use in the treatment of epilepsy is limited because of adverse effects, loss of efficacy (tolerance), and development of physical and psychological dependence. BZDs act as positive allosteric modulators of the inhibitory neurotransmitter GABA by binding to the BZD recognition site (“BZD receptor”) of the GABAA receptor. Traditional BZDs such as diazepam or… Expand
Single dose efficacy evaluation of two partial benzodiazepine receptor agonists in photosensitive epilepsy patients: A placebo-controlled pilot study
TLDR
The study substantiates previous pre-clinical experiments that abecarnil exerts pronounced anti-seizure activity and suggests that the anxiolytic activity of abec Carnil would be an added advantage when using this compound in epilepsy patients. Expand
Experimental GABA A Receptor Agonists and Allosteric Modulators for the Treatment of Focal Epilepsy
TLDR
Several compounds with more selective action on GABA A receptors have the potential to become effective drugs against specific subtypes of focal-onset epilepsy, but their development needs time, and in the near future only one or two new GABA A agonists to obtain marketing authorization for focal epilepsy. Expand
Investigating the potential of the anti-epileptic drug imepitoin as a treatment for co-morbid anxiety in dogs with idiopathic epilepsy
TLDR
Imepitoin does not appear to improve anxiety-related behaviour in dogs with IE treated with this medication for its anti-epileptic effects; however, imepitoin did not appear effective in reducing seizure frequency in a minority of cases. Expand
Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Characterization in Rodent Seizure and Epilepsy Models
TLDR
Padsevonil demonstrated robust efficacy across a broad range of rodent seizure and epilepsy models, several representing drug-resistant epilepsy, and its efficacy extended beyond the combination of drugs interacting separately with SV2 or the benzodiazepine site. Expand
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
TLDR
Knowing knowledge of the pharmacokinetics, antiseizure efficacy and spectrum, and adverse effect profiles of currently used ASMs is an essential component of treating epilepsy successfully and maintaining a high quality of life for every patient, particularly those receiving polypharmacy for drug-resistant seizures. Expand
Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABAA Receptor
TLDR
Padsevonil is a first-in-class AED candidate with a unique target profile allowing for presynaptic and postsynaptic activity and displayed nanomolar affinity for the three synaptic vesicle 2 protein isoforms and micromolar affinityFor the benzodiazepine binding site on GABAA receptors. Expand
Imepitoin Shows Benzodiazepine-Like Effects in Models of Anxiety
TLDR
In rats and mice, imepitoin showed similar anxiolytic activities as benzodiazepines but without producing the known adverse reactions of benzODiazepines such as sedation. Expand
GABA Receptors: Pharmacological Potential and Pitfalls.
TLDR
The aim of this review is to briefly summarize the key pharmacological properties of GABA receptors, and to present selected novel findings with the potential to open new perspectives in the development of more effective therapeutic strategies. Expand
The effect of imepitoin, a recently developed antiepileptic drug, on thyroid parameters and fat metabolism in healthy Beagle dogs.
TLDR
As the use of imepitoin gains popularity, its effect on serum thyroid parameters warrants further investigation since long-term PB administration influences thyroid parameters in dogs, which could lead to misinterpretation of laboratory results and incorrect diagnosis of thyroidal illness. Expand
International Union of Basic and Clinical Pharmacology. CVI: GABAA Receptor Subtype- and Function-selective Ligands: Key Issues in Translation to Humans
TLDR
An up-to-date review on the currently available GABAA receptor subtype-selective ligands and proposals for the future development of ligands with better anxioselectivity in humans are made. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 69 REFERENCES
Partial agonists of benzodiazepine receptors for the treatment of epilepsy, sleep, and anxiety disorders.
TLDR
Comparison of fractional receptor occupancy required for the various effects of both full and partial agonists confirm earlier suggestions that receptor reserves for the individual effects differ with the same order. Expand
Anticonvulsant Efficacy of the Low‐affinity Partial Benzodiazepine Receptor Agonist ELB 138 in a Dog Seizure Model and in Epileptic Dogs with Spontaneously Recurrent Seizures
TLDR
Partial allosteric modulators, which have a low intrinsic activity at the BZD recognition site of the GABAA receptor, might eventually overcome the limitations of full agonists such as diazepam (DZP). Expand
Partial agonists of the benzodiazepine receptor: from animal data to results in patients.
  • W. Haefely
  • Chemistry, Medicine
  • Advances in biochemical psychopharmacology
  • 1988
TLDR
Concepts are presented here that could explain the modulatory function of the BZR, and a number of factors are proposed to determine the pharmacological and therapeutic profile of B zR ligands: intrinsic efficacy at the BzR, density of GABAA-BZR on neurons, functional reserve in GAB AA-BzRs, the intensity of the GABAergic input to a neuron, and the excitatory neuronal state. Expand
The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs.
TLDR
The study demonstrates that low-affinity partial agonists at the benzodiazepine site of the GABAA receptor, such as imepitoin, offer advantages as a new category of AEDs. Expand
Abecarnil: a novel anxiolytic with mixed full agonist/partial agonist properties in animal models of anxiety and sedation.
TLDR
It is shown that with the discovery of a number of subtypes of y-amino- butyric acid type A (GABAA) receptors, a second approach has become feasible to achieve a better dissociation of the effects of benzodiazepine-receptor ligands. Expand
Novel anxiolytics that act as partial agonists at benzodiazepine receptors.
TLDR
Partial agonists for the benzodiazepine modulatory site on the GABAA complex have been developed and their pharmacological profiles can be interpreted to suggest that neurons mediating anticonvulsant and anti-anxiety effects do indeed have a higher receptor reserve than neuronsmediating other unwanted effects. Expand
The novel anxiolytic ELB139 displays selectivity to recombinant GABAA receptors different from diazepam
TLDR
The functional properties of 1-(4-chloro-phenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on (ELB139) in the presence and absence of the BZ receptor antagonist flumazenil are described and the properties were measured with the whole-cell variation of the patch-clamp technique and compared to those of diazepam. Expand
Mechanisms Underlying Tolerance after Long-Term Benzodiazepine Use: A Future for Subtype-Selective GABAA Receptor Modulators?
TLDR
There is no convincing evidence that tolerance occurs with α subunit subtype-selective compounds acting at the benzodiazepine site, and it appears that either different (simultaneous) tolerance mechanisms occur depending on the benzdiazepine effect, or that the tolerance-inducing mechanism depends on the activated GABAA receptor subtypes. Expand
Anxioselective anxiolytics: on a quest for the Holy Grail.
  • P. Skolnick
  • Medicine
  • Trends in pharmacological sciences
  • 2012
TLDR
The evolution of a quest, spanning four decades, for molecules that retain the rapid and robust anti-anxiety actions of benzodiazepines without the side effects that limit their usefulness is discussed. Expand
Characterization in Rats of the Anxiolytic Potential of ELB139 [1-(4-Chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a New Agonist at the Benzodiazepine Binding Site of the GABAA Receptor
TLDR
Evaluating the pharmacological profile of ELB139 in different models of anxiety concluded that it elicits strong effects on anxiety-related behavior in rats mediated by its benzodiazepine-like activity without showing sedation or the development of tolerance, a major side effect of Benzodiazepines. Expand
...
1
2
3
4
5
...